Acumen Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Acumen Pharmaceuticals Inc cash flow-to-debt ratio. Acumen Pharmaceuticals Inc (ABOS) has a Cash Flow-to-Debt Ratio of -0.52x as of March 2026, meaning its operating cash flow of $-24.13 Million could theoretically repay -1% of its total liabilities ($46.15 Million) in one year. See Acumen Pharmaceuticals Inc (ABOS) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Acumen Pharmaceuticals Inc (2019–2025)
Cash flow-to-debt ratio of Acumen Pharmaceuticals Inc from 2019 to 2025. Historical debt coverage capacity for Acumen Pharmaceuticals Inc across 7 annual periods. Also explore ABOS shareholders equity momentum to track the company's year-over-year net asset growth rate.
Acumen Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Acumen Pharmaceuticals Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Acumen Pharmaceuticals Inc. For the full cash flow conversion analysis, see Acumen Pharmaceuticals Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.20x | $-115.54 Million | $52.40 Million | ▼ -46.2% |
| 2024 | -1.51x | $-86.22 Million | $57.18 Million | ▼ -51.1% |
| 2023 | -1.00x | $-43.06 Million | $43.15 Million | ▲ +77.8% |
| 2022 | -4.50x | $-35.15 Million | $7.81 Million | ▼ -29.0% |
| 2021 | -3.49x | $-17.96 Million | $5.15 Million | ▼ -2851.9% |
| 2020 | -0.12x | $-7.45 Million | $63.02 Million | ▲ +67.5% |
| 2019 | -0.36x | $-6.82 Million | $18.74 Million | — |